Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction.

The kidney is one of the major organs drug toxicity may target. Some renal safety biomarkers have been proposed to measure kidney injury and function accordingly. Despite the widespread use for diagnosis and monitoring of renal injury and function for decades, serum creatinine and blood urea nitrogen are nonspecific biomarkers with insensitive and delayed response in the clinical setting. There is an urgent need to identify and qualify novel kidney safety biomarkers that would be used to detect and predict drug-induced nephrotoxicity in preclinical toxicological studies, clinical trials and patient care in sequence. To do that, eight novel renal safety biomarkers have been well characterized and qualified for preclinical drug safety screening, and their clinical bridging validation is underway as well. Of them, some are used to detect or predict proximal tubular injury, and others are used to diagnose and monitor glomerular damage. Thus, measurement of a panel of kidney safety biomarkers in parallel would help maximally capture all potential safety signals for a more informative decision to be made in drug research and development as well as for optimal selection of the drug and its dose in clinical practice.

[1]  J. Bonventre,et al.  Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. , 2002, Kidney international.

[2]  B. Rosenzweig,et al.  Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. , 2011, Kidney international.

[3]  M. Stonard,et al.  Assessment of renal function and damage in animal species . A review of the current approach of the academic, governmental and industrial institutions represented by the animal clinical chemistry association , 1990, Journal of applied toxicology : JAT.

[4]  A. Kribben,et al.  Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. , 2004, Clinical chemistry.

[5]  C. Ponticelli,et al.  Management of drug toxicity in patients with renal insufficiency , 2010, Nature Reviews Nephrology.

[6]  D. Choudhury,et al.  Drug-associated renal dysfunction and injury , 2006, Nature Clinical Practice Nephrology.

[7]  Ronald P. Brown,et al.  Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  F. Di Maggio,et al.  BIOMARKERS OF ACUTE RENAL INJURY AND RENAL FAILURE , 2006, Shock.

[9]  L. Stevens,et al.  Serum cystatin C as a marker of glomerular filtration rate , 2006, Current opinion in nephrology and hypertension.

[10]  J. Bonventre Kidney Injury Molecule‐1 (KIM‐1): A specific and sensitive biomarker of kidney injury , 2008, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[11]  Joseph V Bonventre,et al.  Next-generation biomarkers for detecting kidney toxicity , 2010, Nature Biotechnology.

[12]  A. Grubb,et al.  Renal handling of radiolabelled human cystatin C in the rat. , 1996, Scandinavian journal of clinical and laboratory investigation.

[13]  Joseph V Bonventre,et al.  Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. , 2006, American journal of physiology. Renal physiology.

[14]  Y. Sohn,et al.  Serum cystatin C for estimation of residual renal function in children on peritoneal dialysis , 2011, Pediatric Nephrology.

[15]  R. Beyer,et al.  Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  S. Pettit,et al.  Evaluation of Novel Biomarkers of Nephrotoxicity in Two Strains of Rat Treated with Cisplatin , 2010, Toxicologic pathology.

[17]  J Concato,et al.  Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. , 2008, Kidney international.

[18]  Philip Hewitt,et al.  Performance of novel kidney biomarkers in preclinical toxicity studies. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  G. D'Amico,et al.  Pathophysiology of proteinuria. , 2003, Kidney international.

[20]  S. Waikar,et al.  Biomarkers for the diagnosis of acute kidney injury , 2007, Current opinion in nephrology and hypertension.

[21]  G. Betton,et al.  Application of Dolichos biflorus in immunoassay detection of kidney collecting duct biomarkers , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[22]  C. Peck,et al.  A roadmap for biomarker qualification , 2010, Nature Biotechnology.

[23]  J. Bonventre,et al.  Biomarkers of acute kidney injury. , 2008, Annual review of pharmacology and toxicology.

[24]  P. H. Bach,et al.  Renal Papillary Necrosis—40 Years On , 1998, Toxicologic pathology.

[25]  Kazuo T. Suzuki,et al.  Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam , 2005, Archives of Toxicology.

[26]  N. Frangogiannis,et al.  Biomarkers: hopes and challenges in the path from discovery to clinical practice. , 2012, Translational research : the journal of laboratory and clinical medicine.

[27]  M. Shlipak,et al.  Update on cystatin C: new insights into the importance of mild kidney dysfunction , 2006, Current opinion in nephrology and hypertension.

[28]  J. Bonventre,et al.  Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. , 2008, Kidney international.

[29]  B. Molitoris,et al.  Controversies in nephrology: response to 'renal albumin handling, facts, and artifacts'. , 2007, Kidney international.

[30]  W. Hiddemann,et al.  Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. , 2000, Anticancer research.

[31]  J. Lewis,et al.  Microalbuminuria in Type 2 Diabetes and Hypertension , 2008, Diabetes Care.

[32]  A. Thompson Proteinuria as a surrogate end point—more data are needed , 2012, Nature Reviews Nephrology.

[33]  Joseph V Bonventre,et al.  Biomarkers of nephrotoxic acute kidney injury. , 2008, Toxicology.

[34]  Amy G. Aslamkhan,et al.  Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury , 2010, Nature Biotechnology.

[35]  J. Bonventre,et al.  Kidney Injury Molecule-1 ( Kim-1 ) : A Tissue and Urinary Biomarker for Nephrotoxicant-Induced Renal Injury . , 2003 .

[36]  Timothy A Bertram,et al.  Identification of putative gene based markers of renal toxicity. , 2004, Environmental health perspectives.

[37]  R. Atkins,et al.  Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. , 2001, The American journal of pathology.

[38]  Baolong Lu,et al.  Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  T. Skopek,et al.  A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function , 2010, Nature Biotechnology.

[40]  Joseph V. Bonventre,et al.  Kidney Injury Molecule-1 (KIM-1), a Putative Epithelial Cell Adhesion Molecule Containing a Novel Immunoglobulin Domain, Is Up-regulated in Renal Cells after Injury* , 1998, The Journal of Biological Chemistry.

[41]  M. Miyamoto,et al.  Urinary cystatin C as a biomarker for acute kidney injury and its immunohistochemical localization in kidney in the CDDP-treated rats. , 2012, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[42]  A. Durrbach,et al.  Urinary cystatin C as a specific marker of tubular dysfunction , 2006, Clinical chemistry and laboratory medicine.

[43]  A. Arısoy,et al.  Acute effects of gentamicin on glomerular and tubular functions in preterm neonates , 2006, Pediatric Nephrology.

[44]  V. Jeevanandam,et al.  Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. , 2008, Kidney international.

[45]  N. Brunskill,et al.  Thiazolidinediones Inhibit Albumin Uptake by Proximal Tubular Cells through a Mechanism Independent of Peroxisome Proliferator Activated Receptor Gamma , 2006, American Journal of Nephrology.

[46]  M. Weber,et al.  Alpha 1-microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. , 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[47]  B. Molitoris,et al.  The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. , 2007, Kidney international.

[48]  A. Kribben,et al.  Early detection of acute renal failure by serum cystatin C. , 2004, Kidney international.

[49]  M. Rosenberg,et al.  Clusterin and the kidney. , 1995, Experimental nephrology.

[50]  V. Dharnidharka,et al.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.

[52]  D. Gerhold,et al.  Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies , 2010, Nature Biotechnology.

[53]  G. Remuzzi,et al.  Time to abandon microalbuminuria? , 2006, Kidney international.

[54]  E. Lamb,et al.  Alpha1-microglobulin is stable in human urine ex vivo. , 2002, Clinical chemistry.

[55]  J. Westhuyzen Cystatin C: a promising marker and predictor of impaired renal function. , 2006, Annals of clinical and laboratory science.

[56]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[57]  E. Christensen,et al.  Controversies in nephrology: renal albumin handling, facts, and artifacts! , 2007, Kidney international.

[58]  G. Remuzzi,et al.  Proteinuria should be used as a surrogate in CKD , 2012, Nature Reviews Nephrology.

[59]  M. Perazella,et al.  Drug-induced acute interstitial nephritis , 2010, Nature Reviews Nephrology.

[60]  Syril Pettit,et al.  Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[61]  S. Pennathur,et al.  Marking renal injury: can we move beyond serum creatinine? , 2012, Translational research : the journal of laboratory and clinical medicine.

[62]  Federico Goodsaid,et al.  Evolution of biomarker qualification at the health authorities , 2010, Nature Biotechnology.

[63]  M. Kuiper,et al.  Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy , 2010, Intensive Care Medicine.

[64]  Frank D Sistare,et al.  Research at the interface of industry, academia and regulatory science , 2010, Nature Biotechnology.

[65]  Serafino Pantano,et al.  Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury , 2010, Nature Biotechnology.

[66]  A. Marshall,et al.  Urinary Clusterin in Chronic Nephrotoxicity in the Rat , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[67]  A. Gotoh,et al.  Measurement of cystatin-C and creatinine in urine. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[68]  N. Gretz,et al.  Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries , 2002, Cell and Tissue Research.

[69]  Frank D Sistare,et al.  Towards consensus practices to qualify safety biomarkers for use in early drug development , 2010, Nature Biotechnology.

[70]  John A Kellum,et al.  Acute renal failure in critically ill patients: a multinational, multicenter study. , 2005, JAMA.

[71]  J. Kellum,et al.  Epidemiology of acute kidney injury. , 2010, Contributions to nephrology.

[72]  P. Cochat,et al.  Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma , 1998, Pediatric Nephrology.

[73]  Philip S Li,et al.  Measurement of Urinary Clusterin as an Index of Nephrotoxicity , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[74]  T. Uehara,et al.  Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. , 2010, Toxicology.

[75]  Jonathan Himmelfarb,et al.  Spectrum of acute renal failure in the intensive care unit: the PICARD experience. , 2004, Kidney international.

[76]  W. Comper,et al.  Disease-dependent mechanisms of albuminuria. , 2008, American journal of physiology. Renal physiology.